Propofol


GABA-A receptor positive allosteric modulator (intravenous anesthetic)

An alkylphenol intravenous general anesthetic; the most widely used induction anesthetic and the agent in Michael Jackson’s death.

Abstract

Propofol (2,6-diisopropylphenol; CAS 2078-54-8; molecular formula C12H18O; molecular weight 178.27) is an alkylphenol intravenous general anesthetic developed at ICI (now AstraZeneca) and approved by the FDA in 1989 (Diprivan). The compound is a GABA-A receptor positive allosteric modulator at a unique propofol-binding site distinct from the benzodiazepine, barbiturate, and steroid sites; the result is enhanced GABA-mediated chloride conductance and pronounced CNS depression. Formulation is a 1 percent oil-in-water emulsion (the source of the milky appearance). Plasma half-life is biphasic: rapid distribution (2 to 4 minutes) and slower elimination (3 to 12 hours). Approved indications: induction and maintenance of general anesthesia, sedation in ICU. Misuse for amateur sedation is associated with the death of Michael Jackson (2009). Propofol infusion syndrome (rare) involves metabolic acidosis, rhabdomyolysis, and cardiac failure with prolonged high-dose use. Used as the canonical IV anesthetic in research and clinical practice.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph